|
Price: $0.4349
$-0.07 
-13.055%
|
| Day's High:
| $0.4901
| Week Perf:
| -20.93 %
|
| Day's Low: |
$ 0.40 |
30 Day Perf: |
-70.01 % |
| Volume (M): |
751 |
52 Wk High: |
$ 13.43 |
| Volume (M$): |
$ 327 |
52 Wk Avg: |
$0.97 |
| Open: |
$0.49 |
52 Wk Low: |
$0.21 |
|
|
| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
1 |
| Employees |
135 |
| Revenues (TTM) (Millions $) |
-8 |
| Net Income (TTM) (Millions $) |
-39 |
| Cash Flow (TTM) (Millions $) |
-16 |
| Capital Exp. (TTM) (Millions $) |
1 |
Biocept Inc
Biocept Inc is a publicly-traded molecular diagnostics company based in San Diego, California, which specializes in developing liquid biopsy tests to improve the detection and monitoring of various types of cancer.
The company was founded in 1997 and went public in 2014 on the NASDAQ stock exchange under the symbol "BIOC". Since then, Biocept has become a trusted leader in the field of liquid biopsy testing, allowing physicians to analyze circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other cancer biomarkers in the bloodstream. This approach enables doctors to make more informed decisions about cancer diagnoses, treatment plans, and monitoring.
Biocept's proprietary technology platform is called Target Selector, which is designed to capture and analyze rare cells and fragments of cancer DNA circulating in patients' blood. The company's liquid biopsy tests are used to detect, diagnose, and monitor various types of cancer, including lung, breast, colorectal, gastric, prostate, and melanoma.
In addition to its liquid biopsy tests, Biocept also offers a variety of other biomarker assays, including tests for HER2, estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), and more. These assays help doctors to guide targeted cancer therapies and monitor patients' responses to treatment.
Biocept has partnerships with major healthcare providers worldwide, including Quest Diagnostics and the University of Texas MD Anderson Cancer Center. The company also works closely with pharmaceutical companies to develop companion diagnostic tests for their cancer drugs.
Overall, Biocept is committed to advancing the diagnosis and treatment of cancer through innovative liquid biopsy testing, cutting-edge technology, and strategic partnerships with healthcare providers and pharmaceutical companies. The company's mission is to improve patient outcomes and enhance the quality of life for those affected by cancer.
Company Address: 9955 Mesa Rim Road San Diego 92121 CA
Company Phone Number: 320-8200 Stock Exchange / Ticker: NASDAQ BIOC
| BIOC is expected to report next financial results on April 16, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Hologic Inc
Hologic Inc, a leading Medical Laboratories company, recently released its financial results for the fiscal period ending September 30, 2023. The results indicated a significant decline in income and net profits compared to the previous year. Additionally, the company's operating and net margins contracted, while inventories and accounts receivable witnessed fluctuations. This article aims to outline the facts and interpret the financial performance of Hologic Inc in context.
Financial Results:
1. Income and Earnings Per Share (EPS):
- Hologic Inc's income for the most recent fiscal period fell by -22.69% to $0.36 per share, contrasting with $0.47 per share reported in the previous financial reporting period.
- In the preceding financial reporting period, the company recorded an income per share of $-0.16.
- The decline in EPS is noteworthy, as it has decreased by -64.33% to $1.83 per share from $5.13 per share in the preceding fiscal period.
|
|
Hh And L Acquisition Co
As the earnings cycle resumes for the fiscal period of July-September 2023, a number of entities have disclosed their financial results, including several constituents of the Medical Laboratories sector. One such company is Hh And L Acquisition Co (HHLAU), which recently reported an operating loss of $-4.59154 million for the financial interval ending September 30, 2023.
Analyzing HHLAU's Performance
To accurately assess the fiscal period ending in the third quarter of 2023, it is essential to compare it with its performance in the previous year. In Q3 2022, HHLAU recorded an operating loss of $-1.440693 million. The recent increase in operating loss raises concerns about the firm's ability to sustain and nurture potential revenue streams.
The Stakeholder Analysis
A net loss of $4.769 million in the most recent fiscal period raises several red flags for stakeholders of HHLAU. It suggests potential issues within the company's operations, financial management, or market positioning. Stakeholders, such as investors, lenders, and employees, must closely monitor the company's performance to make informed decisions regarding their involvement with HHLAU.
|
|
Absci Corp
Absci Corp: A Closer Look at the Third Quarter Earnings Report
Absci Corp, a generative AI drug creation company, recently released its earnings report for the third quarter of the 2023 earnings season. The report reveals both positive and negative aspects of the company's financial performance during this period.
To begin with, Absci Corp managed to decrease its loss per share to $-0.24 per share, compared to $-0.30 per share in the previous year. This improvement is a positive sign for shareholders, indicating that the company is taking steps to reduce its losses and move towards profitability.
|
|
Aclarion Inc
The stock market is a dynamic arena where investors scrutinize the financial performance of different companies to make informed investment decisions. Aclarion Inc, a Medical Laboratories company, has recently shared its fiscal results for the most recent reporting period. In this article, we will delve into the interesting facts surrounding the company's performance, analyzing its revenue growth, net shortfall, accounts receivable, and provide insights into its future prospects.
Revenue Growth and Market Position:
During the most recent fiscal period, Aclarion Inc reported reaching a flat valuation of $0.00 per share, which was consistent with the previous year's figure. However, it's worth noting that the company's revenue increased moderately by 4.626% to $0.02 million from the corresponding period a year ago. This positive revenue growth places Aclarion Inc in a favorable position within the Medical Laboratories industry, which witnessed an overall 4.27% top-line growth during the same period. Sequentially, Aclarion Inc's revenue advanced by 11.674% from the preceding financial reporting period, demonstrating its ability to sustain growth and expand its market share.
|
|
Opgen Inc
During the past 5 trading days, Opgen Inc's stock experienced a significant decrease of -16.27%. This dip brings the year-to-date performance to an impressive 184.36%. Currently, Opgen Inc's stock is trading on the NASDAQ at a value that is -39.6% below its 52-week average.
Recent financial reports from Opgen Inc show interesting developments. For the interval between July and September 30, 2023, OPGN's deficit has increased by $-0.46 per share when compared to the same period a year prior. On the other hand, the earnings per share have improved from $-0.93 per share in the preceding quarter. This indicates a mixed performance for the company's financial results.
|
| Per Share |
Current |
| Earnings (TTM) |
-5.6 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
- |
| Cash |
6.4 $
|
| Book Value |
0.28 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-5.6 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
- |
| Cash |
6.4 $
|
| Book Value |
0.28 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
